Programmable CAR-T cells
13 programs
Overview
Our Modalities
CRISPR gene editing
5 programs
RNA therapeutics
12 programs
Gene delivery
7 programs
AI-guided biologics
7 programs
AI-generated small molecules
8 programs
OUR PIPELINE
Six Modalities
Four Gates, One Platform
52 programs
Scroll to see all phases →
Channel
01 · DISCOVERY
Target and lead identification
02 · PRECLINICAL
Safety and efficacy models
03 · IND-ENABLING
Tox, PK, CMC for filing
04 · CLINICAL
In human
CELLProgrammable CAR-T cells13 programs
GENECRISPR gene editing5 programs
—
—
RNARNA therapeutics12 programs
—
DLVRGene delivery7 programs
—
BIOAI-guided biologics7 programs
—
MOLAI-generated small molecules8 programs
—
—
—
CELL Programmable CAR-T cells
BCMA
Multiple myeloma
STAGE
Phase I/II
FIRST IN HUMAN
2025
MODALITY
Ex Vivo CAR-T (3rd-gen)
AREA
Oncology / Hematology
STAGE INTENSITY
Discovery
Preclinical
IND-enabling
Clinical
Area filters show only matching wells on the plate above.